US uncertainty weighs on IPO market while UK innovation could benefit

The political and economic turmoil in the United States is uncertainty against the bio-farm, the initial public proposals (IPO) are expected to slow down as investors appreciate the risks.

Changes in policy under the management of President Trump. From the new tariffs, in key health agencies, from sharp reductions to instability that can prevent investments and delay IPO activities. However, while the US market is facing the headscarves, the regulatory dynamics can present new opportunities at the Obgo Biotics Conference in London on April 2.

During the meeting, the experts stressed that the trust of investors in public markets remains fragile, companies should look more and more to alternative funding strategies such as mergers and achievements (M & A). At the same time, the regulatory reorganization in the United States has led to the US Food and Drug Administration (FDA) capabilities, which can create a large business with British medicines and health care products (MHRA).

Biopharma iPos In 2024 he saw a recreation50 companies completing IPOs and totaling $ 8.52 billion. This marked the higher value of IPO since 2021, announcing recovery in public markets, according to Globaldata analysis, parental company. Pharmaceutical technologyA number

Despite this reconstruction, investors collide with updated instability this year. Instability derives from the latest Trump tariff statements and He cuts a reduction to health agenciesIncluding FDA, Disease Control and Prevention Centers (CDC) and National Health Institute (NIH).

“Investors hate uncertainty, and we have a lot of uncertainty right now, unexpected tariff wars, global conflict.

“We could look 18 months of high uncertainty.”

He added that interest rates also make a decision on how to develop biological investment trends. “If interest rates descended, Biotech becomes more [attractive]… We need a certain level of macro stability before IPOs come back. “

The director of the new English biolabs Kiran Gulati stated: “In this environment, companies need to study alternative funding strategies more and more.

“It simply came to our notice then.